论文部分内容阅读
用免疫组化法检测４６例乳腺癌组织中ＥＧＦＲ及ＥＲ，流式细胞技术检测ＤＮＡ倍体状况，结合病理因素及临床随访结果进行分析，结果发现：１）ＥＧＦＲ与ＥＲ呈显著负相关（Ｐ＜０．０５），与肿瘤组织学分级呈显著正相关（Ｐ＜０．０１），不同月经状况、肿瘤大小、淋巴结受累情况及ＴＮＭ分期中ＥＧＦＲ阳性率无显著差异，ＥＧＦＲ阳性患者生存期显著低于ＥＧＦＲ阴性患者的生存期；２）ＤＮＡ含量与ＥＲ呈负相关，与组织学分级，肿瘤大小及ＥＧＦＲ呈显著正相关，ＤＮＡ异倍体患者生存期明显低于二倍体肿瘤患者的生存期（Ｐ＜０．０１）。提示：ＥＧＦＲ、ＤＮＡ可作为乳腺癌预测预后的有效生物学信息。
Immunohistochemistry was used to detect EGFR and ER in 46 cases of breast cancer. Flow cytometry was used to detect DNA ploidy. Combined with pathological factors and clinical follow-up results, we found: 1) EGFR and ER were significantly negatively correlated (P <0.05), positively correlated with tumor histological grade (P<0.01). There was no significant difference in menstrual status, tumor size, lymph node involvement, and EGFR positive rate in TNM staging. EGFR positive patients had significant survival time. Lower than the survival of EGFR-negative patients; 2) DNA content was negatively correlated with ER, and was significantly positively correlated with histological grade, tumor size and EGFR; survival of DNA aneuploid patients was significantly lower than that of patients with diploid tumors Period (P<0.01). Tip: EGFR and DNA can be used as effective biological information to predict prognosis of breast cancer.